Schering-Plough Reduced OTC Sales Forecast Due To GMP Problems
This article was originally published in The Tan Sheet
Executive Summary
Certain OTC products manufactured by Schering-Plough will see reduced sales due to a problematic manufacturing process and control issues cited by FDA, the company said.
You may also be interested in...
Schering-Plough
Sun care sales leaped 28% to $92 mil. in second quarter on initial sell-in of Coppertone Endless Summer sunless tanning lotion, firm tells analysts June 25. Foot care revenues fell 3% to $97 mil. "due to increased competition"; OTC sales dropped 5% to $42 mil. Company previously predicted OTC business shortfall due to GMP problems (1"The Tan Sheet" Feb. 19, p. 7). CEO Richard Kogan says Schering has "made progress toward resolving these manufacturing issues." Net sales and income both were flat at $2.63 bil. and $634 mil., respectively
Schering-Plough
Sun care sales leaped 28% to $92 mil. in second quarter on initial sell-in of Coppertone Endless Summer sunless tanning lotion, firm tells analysts June 25. Foot care revenues fell 3% to $97 mil. "due to increased competition"; OTC sales dropped 5% to $42 mil. Company previously predicted OTC business shortfall due to GMP problems (1"The Tan Sheet" Feb. 19, p. 7). CEO Richard Kogan says Schering has "made progress toward resolving these manufacturing issues." Net sales and income both were flat at $2.63 bil. and $634 mil., respectively
Schering-Plough
Sun care sales leaped 28% to $92 mil. in second quarter on initial sell-in of Coppertone Endless Summer sunless tanning lotion, firm tells analysts June 25. Foot care revenues fell 3% to $97 mil. "due to increased competition"; OTC sales dropped 5% to $42 mil. Company previously predicted OTC business shortfall due to GMP problems (1"The Tan Sheet" Feb. 19, p. 7). CEO Richard Kogan says Schering has "made progress toward resolving these manufacturing issues." Net sales and income both were flat at $2.63 bil. and $634 mil., respectively